Triple combination therapy in patients infected with COVID-19

A prospective multi-center open trial to evaluate the safety and efficacy of triple combination therapy of lopinavir , ritonavir and hydroxychloroquine sulfate in patients infected with COVID-19.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031190227

Enrollment

Registered

2020-02-27

Start date

2020-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients infected with COVID-19 Coronavirus

Interventions

oral administration of lopinavir, ritonavir and hydroxychloroquine with or without oseltamivir

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: positive result for COVID-19 detection test fever above 37.5 degree Celsius, or pneumonia shadow on chest X-ray or CT-scan hospital admission

Exclusion criteria

Exclusion criteria: past history of hypersensitivity to lopinavir, ritonavir, hydroxychloroquine or oseltamivir pregnancy

Design outcomes

Primary

Measure	Time frame
expected value and 95% CI of ratio of C-reactive protein before versus after the treatment	—

Secondary

Measure	Time frame
disappearance rate of COVID-19	—

Contacts

Public ContactTetsuya Nakamura

Gunma University Hospital

nakamurt@gunma-u.ac.jp+81-27-220-8740

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026